Neuropilin-1 is a Host Factor for SARS-CoV-2 Infection by Daly, James L. et al.
CORONAVIRUS
Neuropilin-1 is a host factor for SARS-CoV-2 infection
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Peter J. Cullen1†, Yohei Yamauchi2,12†
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus
disease 2019 (COVID-19), uses the viral spike (S) protein for host cell attachment and entry. The host
protease furin cleaves the full-length precursor S glycoprotein into two associated polypeptides: S1 and
S2. Cleavage of S generates a polybasic Arg-Arg-Ala-Arg carboxyl-terminal sequence on S1, which
conforms to a C-end rule (CendR) motif that binds to cell surface neuropilin-1 (NRP1) and NRP2
receptors. We used x-ray crystallography and biochemical approaches to show that the S1 CendR motif
directly bound NRP1. Blocking this interaction by RNA interference or selective inhibitors reduced SARS-
CoV-2 entry and infectivity in cell culture. NRP1 thus serves as a host factor for SARS-CoV-2 infection
and may potentially provide a therapeutic target for COVID-19.
S
evere acute respiratory syndrome corona-
virus 2 (SARS-CoV-2) is the coronavirus
responsible for the current coronavirus
disease 2019 (COVID-19) pandemic (1, 2).
A marked difference between the spike
(S) protein of SARS-CoV-2 and SARS-CoV is the
presence, in the former, of a polybasic sequence
motif, Arg-Arg-Ala-Arg (RRAR), at the S1/S2
boundary. It provides a cleavage site for a host
proprotein convertase, furin (3–5) (fig. S1A).
The resulting two proteins, S1 and S2, remain
noncovalently associated, with the serine pro-
tease TMPRSS2 further priming S2 (6). Furin-
mediated processing increases infectivity and
affects the tropism of SARS-CoV-2, whereas
furin inhibition diminishes SARS-CoV-2 entry,
and deletion of the polybasic site in the S pro-
tein reduces syncytia formation in cell culture
(3–5, 7).
The C terminus of the S1 protein generated
by furin cleavage has an amino acid sequence
(682RRAR685) that conforms to a [R/K]XX[R/K]
motif, termed the “C-end rule” (CendR) (fig.
S1B) (8). CendR peptides bind to neuropilin-1
(NRP1) and NRP2, transmembrane receptors
that regulate pleiotropic biological processes,
including axon guidance, angiogenesis, and
vascular permeability (8–10). To explore the
possibility that the SARS-CoV-2 S1 protein
may associate with neuropilins, we generated
a green fluorescent protein (GFP)–tagged S1
construct (GFP-S1) (fig. S1C). When expressed
in human embryonic kidney 293T (HEK293T)
cells engineered to express the SARS-CoV-2
receptor angiotensin-converting enzyme 2
(ACE2), GFP-S1 immunoprecipitated endog-
enous NRP1 and ACE2 (Fig. 1A). We tran-
siently coexpressed NRP1-mCherry and either
GFP-S1 or GFP-S1 DRRAR (a deletion of the
terminal 682RRAR685 residues) in HEK293T
cells. NRP1 immunoprecipitated the S1 pro-
tein, and deletion of the CendR motif re-
duced this association (Fig. 1B). Comparable
binding was also observed with mCherry-
NRP2, a receptor with high homology to
NRP1 (fig. S1, D and E). In both cases, residual
binding was observed with the DRRARmutant,
indicating an additional CendR-independent
association between neuropilins and the S1
protein.
To probe the functional relevance of this
interaction, we generated HeLa wild-type and
NRP1 knockout (KO) cell lines stably ex-
pressing ACE2, designated as HeLawt+ACE2
and HeLaNRP1KO+ACE2, respectively (the level
of ACE2 expression was comparable between
these lines) (fig. S1F). Using a clinical isolate
SARS-CoV-2 (SARS-CoV-2/human/Liverpool/
REMRQ001/2020), we performed viral infec-
tion assays and fixed the cells at 6 and 16 hours
postinfection (hpi). SARS-CoV-2 infection was
reduced in HeLaNRP1KO+ACE2 relative to
HeLawt+ACE2 (Fig. 1C). HeLa cells lacking
ACE2 expression were not infected (fig. S1G).
In Caco-2 cells, a human colon adenocarci-
noma cell line endogenously expressing ACE2
and widely used in COVID-19 studies, the
suppression of NRP1 expression by short
hairpin RNA (shRNA) greatly reduced SARS-
CoV-2 infection at both 7 and 16 hpi, respec-
tively, whereas that of vesicular stomatitis
virus (VSV) pseudotyped with VSV-G was
unaffected (Fig. 1D and figs. S1H and S2A). To
determine if NRP1 was required for early
virus infection, we established a sequential
staining procedure using antibodies against
SARS-CoV-2 S and N proteins to distinguish
extracellular and intracellular viral particles
(fig. S2B). Although NRP1 depletion did not
affect SARS-CoV-2 binding to the Caco-2 cell
surface (Fig. 1E), virus uptake was halved in
NRP1-depleted cells compared to control cells
after 30 min of internalization (Fig. 1F). Thus,
NRP1 enhances SARS-CoV-2 entry and infection.
We also observed that SARS-CoV-2–infected
HeLawt+ACE2 cells displayed a multinucleated
syncytia cell pattern, as reported by others (Fig.
1C) (5). Using an image analysis algorithm and
supervised machine learning (fig. S2, C to F)
(11), we quantified syncytia of infectedHeLawt+
ACE2 andHeLaNRP1KO+ACE2 cells. At 16 hpi,
themajority of HeLawt+ACE2 cells formed syn-
cytia, whereas in HeLaNRP1KO+ACE2 cells, this
phenotype was reduced (fig. S2G). When in-
fected with a SARS-CoV-2 isolate lacking the
furin cleavage site (SARS-CoV-2 DS1/S2) (fig.
S1A), the differences in infection and syncy-
tia formation were less pronounced (fig. S2,
H and I). However, a significant decrease in
infection of HeLaNRP1KO+ACE2 was still ob-
served at 16 hpi, indicating that NRP1 may
additionally influence infection through a
CendR-independent mechanism (fig. S2H).
The extracellular regions of NRP1 andNRP2
are composed of two CUB domains (a1 and
a2), two coagulation factor domains (b1 and
b2), and a MAM domain (9). Of these, the b1
domain contains the specific binding site for
CendR peptides (fig. S3A) (12). Accordingly,
the mCherry-b1 domain of NRP1 immunopre-
cipitated GFP-S1, and a shortened GFP-S1
construct spanning residues 493 to 685 (figs.
S1C and S3B). Isothermal titration calorime-
try (ITC) established that the b1 domain of
NRP1 directly bound a synthetic S1 CendR
peptide (679NSPRRAR685) with an affinity of
20.3 mM at pH 7.5, which was enhanced to
13.0 mM at pH 5.5 (Fig. 2A). Binding was not
observed to an S1 CendR peptide in which the
C-terminal arginine was mutated to alanine
(679NSPRRAA685) (Fig. 2A). We cocrystallized
the NRP1 b1 domain in complex with the S1
CendR peptide (Fig. 2B). The resolved 2.35-Å
structure revealed four molecules of b1 with
electron density of the S1 CendR peptide
clearly visible in the asymmetric unit (fig.
S3C). S1 CendR peptide binding displayed
strong similarity to the previously solved
structure of NRP1 b1 domain in complex with
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its endogenous ligand VEGF-A164 (Fig. 2B and
fig. S3D) (12). The key residues responsible for
contacting the C-terminal R685 of the CendR
peptide —Y297, W301, T316, D320, S346, T349
and Y353—are almost identical between the
two structures (Fig. 2B and fig. S3D). The R682
and R685 side chains together engage NRP1
via stacked cation-p interactions with NRP1
side chains of Y297 and Y353. By projecting
these findings onto the structure of the NRP1
ectodomain, the b1 CendR binding pocket ap-
pears to be freely accessible to the S1 CendR
peptide (fig. S3E) (13).
Site-directed mutagenesis of the S1 R685
residue to aspartic acid drastically reduced
GFP-S1493-685 immunoprecipitation bymCherry-
b1, confirming the critical role of the C-terminal
arginine (Fig. 2C). Mutagenesis of the T316
residue within the mCherry-b1 domain of
NRP1 to arginine also reduced association
with GFP-S1493-685, consistent with its inhib-
itory impact on VEGF-A164 binding (12) (Fig.
2D). Accordingly, incubation of mCherry-b1
with VSV particles pseudotypedwith trimeric
S resulted in immunoprecipitation of processed
forms of S1, which was dependent on the T316
residue (fig. S3F). Next, we transiently expressed
either GFP, full-length NRP1 wt-GFP, or full
length NRP1-GFP harboring the T316R muta-
tion in HeLaNRP1KO+ACE2 cells. GFP expression
and ACE2 expression levels were comparable
and both constructs retained similar cell surface
localization (fig. S3, G and H). SARS-CoV-2
infection was significantly enhanced in cells
expressing NRP1 wt-GFP compared to GFP
control, whereas it was not enhanced in cells
expressing the T316R mutant (Fig. 2E). Thus,
the SARS-CoV-2 S1 CendR and NRP1 interac-
tion promotes infection.
To establish the functional relevance of the
S1 CendR-NRP1 interaction, we screenedmono-
clonal antibodies (mAb#1, mAb#2, mAb#3)
raised against the NRP1 b1b2 ectodomain.
All three bound to the NRP1 b1b2 domain,
displayed staining by immunofluorescence
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Fig. 1. NRP1 Interacts with S1 and enhances SARS-CoV-2 infection.
(A) HEK293T cells transduced to express ACE2 were transfected to express
GFP or GFP-tagged S1 and lysed after 24 hours. The lysates were subjected to
GFP-nanotrap, and the immune isolates were blotted for ACE2 and NRP1 (N = 3
independent experiments). (B) HEK293T cells were cotransfected to express GFP-
tagged S1 or GFP-S1 DRRAR and mCherry or mCherry-tagged NRP1 and subjected to
GFP-nanotrap (N = 5 independent experiments). Two-tailed unpaired t test; P =
0.0002. (C) HeLawt+ACE2 and HeLaNRP1 KO+ACE2 cells were infected with SARS-CoV-2.
Cells were fixed at 6 or 16 hpi and stained for N protein (magenta) and Hoechst (cyan),
and virus infectivity was quantified (N = 3 independent experiments). Two-tailed
unpaired t test; P = 0.00002 and 0.00088. Scale bar, 200 mm. (D) Caco-2 cells
expressing shRNA against NRP1 or a nontargeting control (SCR) were infected with
SARS-CoV-2 and fixed at 7 or 16 hpi. The cells were stained for N protein (magenta) and
Hoechst (cyan), and infectivity was quantified (N = 3 independent experiments). Two-
tailed unpaired t test; P = 0.0005 and 0.00032. Scale bar, 500 mm. (E) Caco-2 shSCR
or shNRP1 cells were inoculated with a multiplicity of infection (MOI) = 50 of SARS-
CoV-2 and incubated in the cold for 60 min, and fixed. A two-step antibody staining
procedure was performed with antibodies against S and N to distinguish external
(green) and total (red) virus particles, and the binding of particles per cell was quantified
for >3300 particles per condition (N = 3 independent experiments). Two-tailed
unpaired t test; P = 0.6859. (F) Caco-2 shSCR or shNRP1 cells were bound with
SARS-CoV-2 as in (E), followed by incubation at 37°C for 30 min. The cells were
fixed and stained as in (E). Viral uptake was quantified for >4200 particles
per condition (N = 3 independent experiments). Two-tailed unpaired t test; P =
0.00079. Scale bars [(E) and (F)], 10 mm and 200 nm (magnified panels). The
square regions were enlarged. The bars, error bars, and circles and triangles
represent the mean, SEM (B) and SD [(C) to (F)], and individual data points,
respectively. ***P < 0.001, ****P < 0.0001. ns, not signficant.
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in NRP1-expressing PPC-1 (human primary
prostate cancer) cells but not in M21 (human
melanoma) cells that do not express NRP1
(fig. S4A) (8), and stained the extracellular
domain of NRP1-GFP expressed in cells (fig.
S4B). Of these antibodies, mAb#3, and to a
lesser extent mAb#1, bound to the CendR-
binding pocket with high specificity, as de-
fined by reduced ability to bind to a b1b2
mutant that targets residues (S346, E348,
T349) at the opening of the binding pocket
(Fig. 3A) (12). Incubation of Caco-2 cells with
mAbs#1 and 3 reduced SARS-CoV-2 infection
compared to a control mAb targeting avian
influenza A virus (H11N3) hemagglutinin (Fig.
3B). Consistent with this, mAb#3 inhibited
binding of GFP-S1493-685 and mCherry-b1 (Fig.
3C). As a comparison, Caco-2 and Calu-3 cells
were incubated with soluble ACE2, which in-
hibited SARS-CoV-2 infection in both cases
(fig. S4C).
Next, we turned to the small molecule
EG00229, a selective NRP1 antagonist that
binds the b1 CendR binding pocket and in-
hibits VEGF-A binding (Fig. 3D) (14). ITC
established that EG00229 bound to the NRP1
b1 domain with a dissociation constant (Kd)
of 5.1 and 11.0 mM at pH 7.5 and 5.5, respec-
tively (Fig. 3E). EG00229 inhibited the direct
binding between b1 and the S1 CendR pep-
tide, and the immunoprecipitation of GFP-
S1493-685 bymCherry-b1 (Fig. 3E and fig. S4D).
Finally, incubation of Caco-2 cellswith EG00229
reduced the efficiency of SARS-CoV-2 infection
at 7 and 16 hpi (Fig. 3F). Thus, the SARS-CoV-2
interaction with NRP1 can be targeted to re-
duce viral infectivity in relevant human cell
lines (fig. S5).
Cell entry of SARS-CoV-2 depends on prim-
ing by host cell proteases (5, 6, 15). Our data
indicate that a component of SARS-CoV-2 S
protein binding to cell surface neuropilins oc-
curs via the S1 CendR motif generated by the
furin cleavage of S1/S2. Though not affecting
cell surface attachment, this interactionpromotes
entry and infection by SARS-CoV-2 in physiolog-
ically relevant cell lines widely used in the study
of COVID-19. Themolecular basis for the effect is
unclear, but neuropilins are known to mediate
the internalization of CendR ligands through an
endocytic process resembling macropinocytosis,
Daly et al., Science 370, 861–865 (2020) 13 November 2020 3 of 5
Fig. 2. Molecular basis for CendR binding of SARS-CoV-2 S1 with NRP1.
(A) Binding of NRP1 b1 with native (green line) and mutant (orange line) form
of S1 CendR peptide (corresponding to residues 679 to 685) by ITC at two
different pH conditions (N = 3 independent experiments). All ITC graphs
represents the integrated and normalized data fit with 1-to-1 ratio binding.
(B) (Left) NRP1 b1–S1 CendR peptide complex superposed with NRP1 b1–
VEGF-A fusion complex (PDB ID: 4DEQ). Bound peptides are shown in stick
representation. RMSD, root mean square deviation. (Right) Enlarged view
highlighting the binding of S1 CendR peptide b1. Key binding residues on
b1 are shown in stick representation. Abbreviations for the amino acid residues are
as follows: A, Ala; D, Asp; E, Glu; N, Asn; P, Pro; R, Arg; S, Ser; T, Thr; W, Trp; and
Y, Tyr. (C). HEK293T cells were cotransfected with combinations of GFP-tagged
S1493-685 and S1493-685 R685D, and mCherry or mCherry-NRP1 b1, and subjected
to mCherry-nanotrap (N = 5 independent experiments). Two-tailed unpaired
t test; P < 0.0001. (D). HEK293T cells were cotransfected with combinations of
GFP-tagged S1493-685 and mCherry, mCherry-NRP1 b1 or mCherry-NRP1 b1
T316R mutant, and subjected to mCherry-nanotrap (N = 5 independent
experiments). Two-tailed unpaired t test; P < 0.0001. (E) HeLaNRP1KO + ACE2
cells transfected with GFP, NRP1 wt-GFP, or NRP1 T316R-GFP constructs were
infected 24 hours later with SARS-CoV-2. At 16 hpi, the cells were fixed and
stained for SARS-CoV-2-N, and viral infection was quantified in the GFP-positive
subpopulation of cells (N = 3 independent experiments). The percentage of
infection was normalized to that of GFP-transfected cells. Two-tailed unpaired
t test; P = 0.002. The bars, error bars, and circles represent the mean, SEM
[(C) and (D)] and SD (E), and individual data points, respectively. **P < 0.01,
****P < 0.0001. ns, not signficant.
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(8, 16, 17). Notably, gene expression analysis has
revealed an up-regulation of NRP1 and NRP2 in
lung tissue fromCOVID-19 patients (18). A SARS-
CoV-2 virus with a natural deletion of the S1/S2
furin cleavage site demonstrated attenuated
pathogenicity in hamster models (19). NRP1
binding to the CendR peptide in S1 is thus
likely to play a role in the increased infectivity
of SARS-CoV-2 compared with SARS-CoV.
The ability to target this specific interaction
may provide a route for COVID-19 therapies.
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Fig. 3. Selective inhibition of the S1-NRP1 interaction reduces SARS-CoV-2
infection. (A) Enzyme-linked immunosorbent assay of anti-NRP1 monoclonal
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t test; P = 0.0207, 0.2430, 0.0007. (B) Cells were first treated with anti-H11N3
(100 mg/ml) (Ctrl) mAb, mAb#1, mAb#2, or mAb#3 for 1 hour before infection
with SARS-CoV-2. Cells were fixed at 16 hpi and stained for N protein (magenta)
and Hoechst (cyan) (N = 3 independent experiments). Two-tailed unpaired t test;
P = 0.015, 0.36, 0.0003. Scale bar, 500 mm. (C) HEK293T cells were cotransfected
with combinations of mCherry or mCherry-b1 and GFP-tagged S1493-685 and
subjected to mCherry-nanotrap with or without coincubation with mAb#3
(N = 3 independent experiments). Two-tailed unpaired t test; P = 0.0143. (D) NRP1
b1–S1 CendR peptide complex superimposed with NRP1 b1–EG00229 inhibitor
complex (PDB ID:3I97). Key binding residues on b1, bound peptides, and EG00229
are shown in stick representation. (E) ITC analysis of EG00229 binding to b1 domain
of NRP1 at two different pH conditions. Preincubation with EG00229 blocks S1
CendR peptide binding (orange line), and the CendR peptide can reduce binding of
EG00229 (green line) (N = 3 independent experiments). All ITC graphs represent
the integrated and normalized data fit with 1-to-1 ratio binding. (F). Cells were
first treated with 100 mM EG00229 or dimethyl sulfoxide before infection with
SARS-CoV-2. Cells were fixed at 7 and 16 hpi and stained for N protein (magenta)
and Hoechst (cyan) (N = 3 independent experiments). The square regions were
enlarged. Scale bars, 500 mm and 100 mm (magnified panels). Two-tailed unpaired
t test; P = 0.0059 and 0.0013. The bars, error bars, and circles and triangles
represent the mean, SEM (C) and SD [(A), (B), and (F)], and individual data
points, respectively. *P < 0.05, **P < 0.01, ***P < 0.001.
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